Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons
Heather J. Zar, Louis J. Bont, P Manzoni, Flor M. Muñoz et autres
2 citationsArchives of Pediatrics and Adolescent Medicine
Anthonet Koen
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
60Publications signalées
10033Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
SARS-CoV-2 and COVID-19 ResearchRespiratory viral infections researchPneumonia and Respiratory InfectionsCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy
Publications récentes
Waning of measles immunity by 5 years of age following an accelerated two-dose measles vaccine schedule at 6 and 12 months in South African children: an observational cohort study
Daniel Kapelus, Heena Ranchod, Courtney P. Olwagen, Anthonet Koen et autres
1 citationVaccine
Immunogenicity through to Five Years of Age Following a Single Compared with Two Dose Primary Series Followed by a Booster Dose of 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine during Infancy: An Open-Label, Randomised, Non-Inferiority Trial
Daniel Kapelus, Dr Courtney Olwagen, Alane Izu, Heena Ranchod et autres
0 citationsSSRN Electronic Journal
Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study
Paul T. Heath, Ntokozo Zuma-Gwala, Rikke Bek Helmig, Elizea Horne et autres
5 citationsThe Lancet Infectious Diseases
Persistence of Antibodies at Three, Four and Five Years of Age to Ten-valent Pneumococcal Polysaccharide Protein D-conjugate Vaccine in South African Children According to HIV Status
Alane Izu, Anthonet Koen, Lisa Jose, Clare Cutland et autres
0 citationsThe Pediatric Infectious Disease Journal
T-cell responses induced by SARS-CoV-2 index-virus nanoparticle protein vaccine to the ancestral and omicron variants 6 months following primary vaccination
Gaurav Kwatra, Marta C. Nunes, Alane Izu, Anthonet Koen et autres
4 citationsCommunications Medicine
P-100. Durable immune response induced by self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidates against variants of concern (VOC) in HIV-negative and people living with HIV (PLWH) populations in South Africa, irrespective of prior SARS-CoV-2 vaccination
Atul Nagare, Élizabeth Martin, Anthonet Koen, Essack Mitha et autres
0 citationsOpen Forum Infectious Diseases
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study
Alane Izu, Eleonora A.M.L. Mutsaerts, Courtney P. Olwagen, Lisa Jose et autres
0 citationsExpert Review of Vaccines
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
Vivek Shinde, Anthonet Koen, Zaheer Hoosain, Moherndran Archary et autres
3 citationsHuman Vaccines & Immunotherapeutics
Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial
Courtney P. Olwagen, Alane Izu, Lara Van der Merwe, Lisa Jose et autres
5 citationsExpert Review of Vaccines
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial
Chijioke Bennett, Zaheer Hoosain, Anthonet Koen, Umesh Lalloo et autres
3 citationsJournal of Infection
Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children
Joseph B. Domachowske, Ulrika Wählby Hamrén, Irfana Banu, Roberta Baronio et autres
26 citationsPEDIATRICS
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.